These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Ongoing 2005-004714-32 A PHASE II, MULTI-CENTER STUDY OF BORTEZOMIB, ADRIAMYCIN, DEXAMETHASONE (PAD) as induction and MELPHALAN 100 mg/m2 (MEL 100) as transplant, IN ELDERLY NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS. not-yet-due
Reported results 2005-004730-41 A PHASE II, MULTI-CENTER STUDY OF MELPHALAN 100 mg/m2 (MEL 100) as transplant, REVLIMID and PREDNISONE (RP) as consolidation and REVLIMID ALONE as maintenance IN ELDERLY NEWLY DIAGNOSED MULTIPLE MYEL... 2023-08-14 due-trials
Ongoing 2005-004745-33 A PHASE III, MULTI-CENTER, RANDOMIZED OPEN LABEL STUDY OF VELCADE, MELPHALAN, PREDNISONE AND THALIDOMIDE V-MPT Versus VELCADE, MELPHALAN, PREDNISONE V-MP IN ELDERLY UNTREATED MULTIPLE... not-yet-due
Ongoing 2006-007087-28 A PHASE II, MULTI-CENTER, OPEN LABEL STUDY OF LENALIDOMIDE, MELPHALAN, PREDNISONE AND THALIDOMIDE R-MPT IN ADVANCED, RELAPSED, REFRACTORY MULTIPLE MYELOMA PATIENTS. not-yet-due
Completed, report not yet due 2007-001610-16 A PHASE 3, MULTICENTRE, RANDOMIZED, CONTROLLED STUDY TO DETERMINE THE EFFICACY AND SAFETY OF LENALIDOMIDE, MELPHALAN AND PREDNISONE (MPR) versus MELPHALAN (200 mg/m2) FOLLOWED BY STEM CELL TRANSPLANT ... 2024-07-01 not-yet-due
Ongoing 2007-003707-12 Tandem Autografting-Allografting after Induction Chemotherapy with “New Drugs” For Newly Diagnosed Myeloma not-yet-due
Ongoing 2007-005563-10 Allogeneic Hematopoietic Cell Transplantation Using a Non-myeloablative Preparative Regimen of Total Lymphoid Irradiation and Anti-Thymocyte Globulin for Patients with Hematologic Malignancies not-yet-due
Completed, but no date, and reported results 2007-006123-13 A MULTICENTER, OPEN LABEL STUDY OF VELCADE, MELPHALAN AND PREDNISONE (VMP) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS bad-data
Reported results 2007-007616-28 A MULTICENTER, OPEN LABEL STUDY OF ORAL REVLIMID AND PREDNISONE (RP) FOLLOWED BY ORAL REVLIMID MELPHALAN AND PREDNISONE (MPR) IN NEWLY DIAGNOSED ELDERLY MULTIPLE MYELOMA PATIENTS 2022-12-22 due-trials
Completed, but no date, and reported results 2007-007939-29 A PHASE II,MULTI-CENTER, OPEN LABEL STUDY OF ORAL LBH589 PLUS MELPHALAN, PREDNISONE AND THALIDOMIDE (LB-MPT)IN ADVANCED, REFRACTORY MULTIPLE MYELOMA PATIENTS. bad-data
Completed, but no date Terminated 2008-004165-26 A MULTICENTER, OPEN-LABEL, PHASE II STUDY OF DASATINIB IN COMBINATION WITH MELPHALAN AND PREDNISONE (D-MP) IN ADVANCED, RELAPSED / REFRACTORY MULTIPLE MYELOMA PATIENTS. bad-data
Reported results Terminated 2008-004529-41 Safety And Efficacy Of Lenalidomide As Maintenance Therapy In Patients With Newly Diagnosed Multiple Myeloma Following A Tandem Autologous-Allogeneic Transplant 2023-02-15 due-trials
Completed, report not yet due 2008-008599-15 A PHASE 3, MULTICENTRE, RANDOMIZED, CONTROLLED STUDY TO DETERMINE THE EFFICACY AND SAFETY OF CYCLOPHOSPHAMIDE, LENALIDOMIDE AND DEXAMETHASONE (CRD) versus MELPHALAN (200 mg/m2) FOLLOWED BY STEM CELL T... 2024-07-01 not-yet-due
Completed, report not yet due 2008-008606-52 A PHASE 3, INTERGROUP MULTICENTRE, RANDOMIZED, CONTROLLED 3 ARM PARALLEL GROUP STUDY TO DETERMINE THE EFFICACY AND SAFETY OF LENALIDOMIDE IN COMBINATION WITH DEXAMETHASONE (Rd) VERSUS MELPHALAN, PREDN... 2024-07-01 not-yet-due
Ongoing 2009-016610-24 Bortezomib, Desametasone e Doxorubicina liposomiale peghilata come terapia di induzione prima di ASCT (autologous stem cell transplantation) ad intensita` ridotta in pazienti anziani affetti da mielom... not-yet-due
Ongoing 2012-000087-15 A PHASE II, MULTI-CENTER, OPEN LABEL STUDY OF CYCLOPHOSPHAMIDE IN MULTIPLE MYELOMA PATIENTS WITH BIOCHEMICAL PROGRESSION DURING LENALIDOMIDE-DEXAMETHASONE TREATMENT FOR RELAPSED/REFRACTORY MULTIPLE MY... not-yet-due
Completed, but no date, and reported results 2012-004063-52 LENALIDOMIDE MAINTENANCE IN MULTIPLE MYELOMA PATIENTS ACHIEVING AT LEAST VGPR AFTER INDUCTION THERAPY: MINIMAL RESIDUAL DISEASE MONITORING MANTENIMENTO CON LENALIDOMIDE IN PAZIENTI CON MIELOMA MU... bad-data
Ongoing 2012-005378-73 Allogeneic Transplantation after a Conditioning with Thiotepa, Busulfan and Fludarabin for the treatment of refractory/early relapsed aggressive B-cell non Hodgkin lymphomas: a Phase II Multi-Center T... not-yet-due
Completed, report not yet due 2013-004166-33 A PHASE III, MULTICENTRE, RANDOMIZED, CONTROLLED STUDY TO DETERMINE THE EFFICACY AND SAFETY OF STANDARD SCHEDULE VERSUS A NEW ALGORITHM OF DOSE REDUCTIONS IN ELDERLY AND UNFIT NEWLY DIAGNOSED MULTIPLE... 2024-07-01 not-yet-due
Ongoing 2014-000130-37 Prospective, phase II study to evaluate the efficacy and the safety of a combination of bendamustine-melphalan as preparative regimen to autologous transplantation of hematopoietic cells for multiple... not-yet-due
Completed, but no date Terminated 2014-000140-15 Comparative Polysomnographic Study of Oxycodone/Naloxone or Pramipexole for the Treatment of Restless Legs Syndrome Studio polisonnografico comparativo ossicodone/naloxone vs pramipexolo nel trat... bad-data
Other 2018-002068-15 CARFILZOMIB - LENALIDOMIDE - DEXAMETHASONE (KRd) versus LENALIDOMIDE - DEXAMETHASONE (Rd) IN NEWLY DIAGNOSED MYELOMA PATIENTS NOT ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION: A RANDOMIZED PHASE ... not-yet-due